pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
raps·23h ago·1 min read
save

EMA publishes guidance on voluntary electronic product information submissions for EU MAAs

Sep 8, 2026·read at raps ↗RegulatoryNeutral

The European Medicines Agency released new guidance detailing how companies should provide electronic product information (ePI) when filing marketing authorization applications under the EU's centralized procedure.

The guidance notes that ePI submission is currently voluntary, pending full implementation of the EU pharmaceutical legislation that will later make it mandatory.

Companies are encouraged to follow the recommendations to prepare for the upcoming requirement, which aims to streamline product information access across the European market.

source

This writeup was produced by pharmadog from original reporting by raps.

Original headline: “EMA issues guidance on submitting ePI ahead of upcoming requirement”

read at raps ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 23h agoRecon: FDA approves AZ’s breast cancer drug over negative adcomm vote; Novartis sees setbacks for drugs targeting cholesterol, m...raps
  • 4d agoThis Week at FDA: Foreign clinical trial scrutiny, botanical drugs, and an EUA declarationraps
  • 5d agoIndustry asks FDA to expand prior knowledge guidanceraps
  • 5d agoRecon: CBER official overruled Replimune melanoma drug rejection; AbbVie claims Phase 3 win for multiple myeloma drugraps
  • 5d agoEuro Roundup: UK government moves to modernize legislative framework for medicines and devicesraps